Xbrane And Biogen Ally On Certolizumab Pegol Biosimilar

Xbrane CEO Martin Åmark Highlights Potential For Xcimzane Rival To Cimzia

 
• By David Wallace
  
Certolizumab Pegol green background
Xbrane has secured Biogen as a partner on its Xcimzane certolizumab pegol biosimilar • Source: molekuul.be / Alamy Stock Photo
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Deals

More from Business